{
    "id": "3aec3da3-a8fc-4996-b2e2-3d4f029e35cf",
    "indications": "Carbidopa, levodopa and entacapone tablets are indicated for the treatment of Parkinson's disease.\n                  Carbidopa, levodopa and entacapone tablets can be used:\n                  \n                     \n                        •To substitute (with equivalent strengths of each of the three components) carbidopa/levodopa and entacapone previously administered as individual products.\n                     \n                        •To replace carbidopa/levodopa therapy (without entacapone) when patients experience the signs and symptoms of end-of-dose “wearing-off” and when they have been taking a total daily dose of levodopa of 600 mg or less and have not been experiencing dyskinesias.",
    "contraindications": "Carbidopa, levodopa and entacapone tablets should be used as a substitute for patients already stabilized on equivalent doses of carbidopa/levodopa and entacapone. However, some patients who have been stabilized on a given dose of carbidopa/levodopa may be treated with carbidopa, levodopa and entacapone tablets if a decision has been made to add entacapone (see below). Therapy should be individualized and adjusted according to the desired therapeutic response.",
    "warningsAndPrecautions": "Carbidopa, levodopa and entacapone tablets are supplied as film-coated tablets for oral administration in the following six strengths:\n                  Carbidopa, levodopa and entacapone film-coated tablets containing 12.5 mg of carbidopa, 50 mg of levodopa, and 200 mg of entacapone.\n                  The round, bi-convex shaped tablets are brownish- or greyish-red, unscored, and embossed “LCE 50” on one side.\n                  \n                     \n                         NDC 0781-5613-01 HDPE bottle of 100 tablets\n                  \n                  Carbidopa, levodopa and entacapone film-coated tablets containing 18.75 mg of carbidopa, 75 mg of levodopa, and 200 mg of entacapone.\n                  The oval-shaped tablets are light brownish red, unscored and embossed with code “LCE 75” on one side.\n                  \n                     \n                         NDC 0781-5625-01 HDPE bottle of 100 tablets\n                  \n                  Carbidopa, levodopa and entacapone film-coated tablets containing 25 mg of carbidopa, 100 mg of levodopa, and 200 mg of entacapone.\n                  The oval-shaped tablets are brownish- or greyish-red, unscored, and embossed “LCE 100” on one side.\n                  \n                     \n                         NDC 0781-5637-01 HDPE bottle of 100 tablets\n                  \n                  Carbidopa, levodopa and entacapone film-coated tablets containing 31.25 mg of carbidopa, 125 mg of levodopa, and 200 mg of entacapone.\n                  The oval-shaped tablets are light brownish red, unscored and embossed with code “LCE 125” on one side.\n                  \n                     \n                         NDC 0781-5641-01 HDPE bottle of 100 tablets\n                  \n                  Carbidopa, levodopa and entacapone film-coated tablets containing 37.5 mg of carbidopa, 150 mg of levodopa, and 200 mg of entacapone.\n                  The elongated-ellipse shaped tablets are brownish- or greyish-red, unscored, and embossed “LCE 150” on one side.\n                  \n                     \n                         NDC 0781-5654-01 HDPE bottle of 100 tablets\n                  \n                  Carbidopa, levodopa and entacapone film-coated tablets containing 50 mg of carbidopa, 200 mg of levodopa, and 200 mg of entacapone.\n                  The oval shaped tablets are dark brownish red, unscored, and embossed “LCE 200” on one side.\n                  \n                     \n                         NDC 0781-5669-01 HDPE bottle of 100 tablets",
    "adverseReactions": "Carbidopa, levodopa and entacapone tablets are contraindicated in patients:\n                  \n                     \n                        •Taking nonselective monoamine oxidase (MAO) inhibitors (e.g., phenelzine and tranylcypromine). These nonselective MAO inhibitors must be discontinued at least two weeks prior to initiating therapy with carbidopa, levodopa and entacapone tablets.\n                     \n                        •With narrow-angle glaucoma.",
    "ingredients": [
        {
            "name": "CARBIDOPA",
            "code": "MNX7R8C5VO"
        },
        {
            "name": "LEVODOPA",
            "code": "46627O600J"
        },
        {
            "name": "ENTACAPONE",
            "code": "4975G9NM6T"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "GLYCERIN",
            "code": "PDC6A3C0OX"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        }
    ],
    "organization": "Sandoz Inc",
    "name": "Carbidopa, Levodopa, and Entacapone",
    "effectiveTime": "20231130"
}